Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18641946 | 0.86 | HPGD (0.54) | APEX1POLBTRPV1HPGDTP53 | |
| SCHEMBL17339470 | 0.85 | APEX1 (0.50) | APEX1POLBTRPV1HPGDTP53 | |
| SCHEMBL29617729 | 0.85 | APEX1 (0.50) | APEX1POLBTRPV1HPGDTP53 | |
| SCHEMBL17339620 | 0.84 | TRPV1 (0.54) | APEX1TRPV1HPGDMAPTALDH1A1 | |
| SCHEMBL17339552 | 0.83 | TRPV1 (0.48) | CTSSAPEX1TRPV1HPGDMAPT | |
| SCHEMBL17339342 | 0.82 | APEX1 (0.58) | APEX1POLBTRPV1HPGDTP53 | |
| SCHEMBL17339460 | 0.78 | HPGD (0.56) | APEX1POLBTRPV1HPGDTP53 | |
| SCHEMBL6024762 | 0.77 | CTSS (0.61) | CTSSPOLBNR1H4 | |
| SCHEMBL17339636 | 0.77 | HPGD (0.74) | POLBTRPV1HPGDTP53GLA | |
| SCHEMBL17339508 | 0.76 | TRPV1 (0.48) | TRPV1HPGDMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3154978-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | LOXO ONCOLOGY INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| EP-3154978-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Redx Pharma Plc (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | REDX PHARMA PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | CTSS 4103/4885APEX1 1934/4885POLB 2100/4885 |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | CTSS 4103/4885APEX1 1934/4885POLB 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.